Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Aujayeb (Newcastle, United Kingdom), K. Jackson (Newcastle, United Kingdom). The UK timed diagnostic lung cancer pathway: a pleural disaster. 1138

Member's Comments

No comment yet.

Related content which might interest you: Rationalising the lung cancer diagnostic pathway with CT triage; a single centre UK experience. Source: Virtual Congress 2020 – Management issues in thoracic oncology Year: 2020 The role of bronchoscopy in the diagnosis of lung cancer: an audit to assess standards Source: Eur Respir J 2001; 18: Suppl. 33, 62s Year: 2001 An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer Source: Annual Congress 2006 - MP11 - An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer Year: 2006 Tissue is the issue and beyond: proper sampling for diagnosis and staging of lung cancer by chest physicians as well as its alternatives Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Assessing the role of pleural fluid in current cancer diagnostic pathway. Source: Virtual Congress 2020 – Management issues in thoracic oncology Year: 2020 Diagnostic investigations in lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=151 Year: 2001 Diagnostic utility of cell block method combined with conventional smear cytology in the diagnosis of exudative pleural effusions accompanying lung cancer Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Management of lung cancer screening and incidental findings as well as their integration in existing lung cancer care Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Is time from "referral to diagnosis" in lung cancer pathway affected by diagnostic test delays? Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Direct to surgery treatment of suspected lung cancer – results from a UK lung cancer multidisciplinary team (MDT) Source: Virtual Congress 2021 – Innovation in thoracic surgery Year: 2021 Reducing delays in lung cancer diagnostic pathways to improve patient experience Source: International Congress 2016 – Quality management and quality of life in lung cancer Year: 2016 Our diagnostic time for lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 322s Year: 2005 Improving standards in flexible bronchoscopy for lung cancer Source: Eur Respir J 2011; 37: 895-901 Year: 2011 The role of diagnostic thoracoscopy in patients with lung cancer and pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 542s Year: 2003 The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Cytological diagnostics of lung cancer: our experience Source: Eur Respir J 2005; 26: Suppl. 49, 306s Year: 2005 The chest physician as the lung cancer patient’s guide: defining the role of the modern day chest physician throughout the lung cancer continuum Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe Source: International Congress 2018 – State of the art session: Thoracic oncology Year: 2018